Tirzepatide

Tirzepatide is a synthetic peptide studied in laboratory research as a dual agonist at GIP and GLP-1 receptors. Research literature has examined its activity in metabolic signaling, insulin-secretion pathway models, and energy-balance regulation. Supplied as lyophilized material for qualified in-vitro research applications.

Compound specifications: Lyophilized powder in sealed vials. Purity verified at ≥99% by independent third-party HPLC analysis. Store in a cool, dry environment; refrigerate after reconstitution per standard laboratory protocol.

What is Tirzepatide?

Tirzepatide (development code LY3298176) is a synthetic 39-amino-acid peptide functioning as a dual receptor co-agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is among the most extensively documented incretin research compounds in the published literature, including the SURPASS and SURMOUNT clinical-trial programs.

In the laboratory, tirzepatide is used as a benchmark dual-agonist for incretin-pathway research — the reference point against which newer multi-receptor compounds are compared. It is supplied here as high-purity lyophilized material strictly for qualified in-vitro and preclinical research use.

Mechanism of Action — Research Overview

Tirzepatide combines GIP-receptor and GLP-1-receptor agonism in a single peptide backbone. Research models examine how this dual engagement produces signaling characteristics distinct from GLP-1-selective agonists — including differential cAMP responses, beta-arrestin recruitment patterns, and receptor-desensitization profiles across cell systems.

Published preclinical and clinical literature explores its influence on glucose-dependent insulin secretion pathways, gastric-emptying rate in study models, and central appetite-signaling circuits. Its well-characterized pharmacology makes it a standard comparator in metabolic-peptide research.

Research Applications

• Dual-incretin (GIP/GLP-1) receptor pharmacology research
• Glucose homeostasis and insulin-secretion signaling models
• Appetite-regulation and energy-intake pathway studies
• Comparator reference for next-generation multi-agonist research
• Receptor trafficking and biased-signaling investigations

Tirzepatide Specifications

Laboratory Handling & Storage

Handle using standard lyophilized-peptide laboratory technique with appropriate PPE. Avoid repeated freeze–thaw cycles after reconstitution; aliquot prepared solutions per protocol and document lot numbers for traceability.

Certificate of Analysis & Quality Assurance

Every batch of Tirzepatide is verified by independent third-party HPLC analysis (identity and purity) before it ships. The certificate of analysis for the current batch is linked on this page and can be reviewed here: view batch COA. Documentation of lot number, test date, and method accompanies each batch.

References

1. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025. PMID: 39536238
2. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024. PMID: 38819983

Note: Tirzepatide is supplied strictly for laboratory research use only. It is not approved for human or veterinary use, and nothing on this page is medical advice or a health claim. All described findings reflect preclinical or published research contexts.

Shipping, Handling & Guarantee

• Fast U.S. shipping: Orders placed before 2:00 PM CT ship the same business day from Minneapolis, MN. Free shipping on orders over $100.
• Lab safety profile: Supplied for laboratory research use only. Handle using appropriate personal protective equipment in a suitable laboratory setting. Not for human or veterinary use.
• Order guarantee: If your order arrives damaged, incorrect, or incomplete, contact us within 48 hours of delivery with photos and we will make it right. See our Return & Refund Policy.